vTv Therapeutics Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
VTVT$21.03-3.3%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except per share data)
(in thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| (Unaudited) · (Unaudited) | ||||
| Revenue | $— | $— | $36,839 | $— |
| Operating expenses: | ||||
| Research and development | 7,531 | 7,020 | 25,279 | 13,953 |
| General and administrative | 4,895 | 3,679 | 14,653 | 10,970 |
| Total operating expenses | 12,426 | 10,699 | 39,932 | 24,923 |
| Operating loss | (12,426) | (10,699) | (3,093) | (24,923) |
| Interest income | 734 | 399 | 2,384 | 1,005 |
| Interest expense | — | (5) | — | (5) |
| Other income (expense), net | 72 | (40) | 169 | (19) |
| Net loss before income taxes and noncontrolling interest | (11,620) | (10,345) | (540) | (23,942) |
| Income tax provision | — | — | — | — |
| Net loss before noncontrolling interest | (11,620) | (10,345) | (540) | (23,942) |
| Less: net loss attributable to noncontrolling interest | — | (1,647) | — | (4,106) |
| Net loss attributable to vTv Therapeutics Inc. | $(11,620) | $(8,698) | $(540) | $(19,836) |
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $(11,620) | $(8,698) | $(540) | $(19,836) |
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $(0.94) | $(1.08) | $(0.04) | $(2.80) |
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 12,423,917 | 8,055,940 | 12,414,224 | 7,080,681 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.